CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Immunotherapy in Renal Cell Carcinoma.
Immunotherapy in Renal Cell Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
从早期 IL-2 时代到当前免疫检查点抑制剂（ICI）联合方案，肾细胞癌（RCC）免疫治疗取得了巨大进步。多种基于 ICI 的疗法显著改善了 RCC 患者结局，部分患者可能获得持久应答。本章回顾转移性 RCC 一线关键 ICI 联合方案的数据及近期辅助免疫治疗数据，还讨论既往接受 ICI 后再次挑战免疫治疗的近期证据，以及 CAR-T 和肠道微生物组干预等新兴免疫疗法策略。最后，作者强调 ICI 治疗 RCC 患者应采用多学科团队方法，包括管理免疫相关不良事件，以及在不断演变的治疗格局中评估减瘤性肾切除术的潜在作用。
There have been tremendous advancements in immunotherapy approaches for patients with renal cell carcinoma (RCC) from the initial interleukin-2 era to the current immune checkpoint inhibitor (ICI) combinations. Several ICI-based therapies have greatly improved outcomes for patients with RCC with the potential for durable responses for a subset of patients. In this chapter, we review the data of key frontline ICI-based combinations for RCC in the metastatic setting and recent data on adjuvant immunotherapy.
We also discuss recent data on the role of immunotherapy rechallenge following prior ICI treatment as well as emerging novel immunotherapy strategies with chimeric antigen receptor (CAR) T and gut microbiome interventions. Lastly, we highlight a multidisciplinary team-based approach for patients with RCC treated with ICI including management of immune-related adverse events as well as potential role of cytoreductive nephrectomy in an evolving treatment landscape.
MEMBER ACCOUNT
登录成功会直接打开下一页。
